Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2019

Open Access 01-09-2019 | Metastasis | Research Article

Elevated expression of GNAS promotes breast cancer cell proliferation and migration via the PI3K/AKT/Snail1/E-cadherin axis

Authors: X. Jin, L. Zhu, Z. Cui, J. Tang, M. Xie, G. Ren

Published in: Clinical and Translational Oncology | Issue 9/2019

Login to get access

Abstract

Purpose

Although it has been well established that G protein plays pivotal roles in physiologic or pathologic conditions, including cancer formation, its role in breast cancer, especially specific subunits, remains largely unknown. Our work aimed to evaluate the correlation of the G protein alpha subunit (GNAS) with breast cancer and to investigate the underlying molecular mechanism.

Methods

The expression of GNAS was determined by breast tumor tissue microarray of 150 patients with complete follow-up information. The correlation between GNAS expression and clinical features was assessed. CCK8, EdU incorporation, flow cytometry, wound healing, transwell, western blot and tumor formation assays were carried out in nude mice to study the biological function of GNAS and the underlying molecular mechanism in breast cancer by silencing GNAS using a specific siRNA.

Results

High GNAS expression showed a close correlation with a reduced overall survival (p = 0.021), frequent distal metastasis (p = 0.026), advanced clinical stage (p = 0.001), stronger cell proliferation (ki67+ positive cell rate, p = 0.0351) and enhanced cancer cell migration, which was further confirmed by in vitro and in vivo assays and might be dependent on the PI3K/AKT/Snail1/E-cadherin axis.

Conclusion

The data suggested that GNAS promoted breast cancer cell proliferation and migration (EMT) through the PI3K/AKT/Snail1/E-cadherin signaling pathway. These findings also indicate that GNAS can serve as a potential prognostic indicator and novel therapeutic target in breast cancer.
Literature
1.
2.
Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, et al. Breast cancer metastasis: challenges and opportunities. Cancer Res. 2009;69:4951.CrossRefPubMed
3.
4.
Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov. 2011;10:47.CrossRefPubMed
5.
6.
O’Hayre M, Vázquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, et al. The emerging mutational landscape of G-proteins and G-protein coupled receptors in cancer. Nat Rev Cancer. 2013;13:412.CrossRefPubMedPubMedCentral
7.
Lu C, Xia J, Zhou Y, Lu X, Zhang L, Gou M, et al. Loss of Gsα impairs liver regeneration through a defect in the crosstalk between cAMP and growth factor signaling. J Hepatol. 2016;64:342–51.CrossRefPubMed
8.
Das R, Esposito V, Abu-Abed M, Anand GS, Taylor SS, Melacini G, et al. cAMP activation of PKA defines an ancient signaling mechanism. Proc Natl Acad Sci USA. 2007;104:93–8.CrossRefPubMed
9.
Beristain AG, Molyneux SD, Joshi PA, Pomroy NC, Di Grappa MA, Chang MC, et al. PKA signaling drives mammary tumorigenesis through Src. Oncogene. 2015;34:1160–73.CrossRefPubMed
10.
Bhat RR, Yadav P, Sahay D, Bhargava DK, Creighton CJ, Yazdanfard S, et al. GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Research and Treatment. 2018;170(2):279–92.CrossRefPubMedPubMedCentral
11.
Rao A, Herr DR. G protein-coupled receptor GPR19 regulates E-cadherin expression and invasion of breast cancer cells. Biochim Biophys Acta (BBA) Mol Cell Res. 2017;186:1318.CrossRef
12.
Liang S, Chen Z, Jiang G, Zhou Y, Liu Q, Su Q, et al. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals. Cancer Lett. 2017;386:12.CrossRefPubMed
13.
Chen M, Gavrilova O, Zhao WQ, Nguyen A, Lorenzo J, Shen L, et al. Increased glucose tolerance and reduced adiposity in the absence of fasting hypoglycemia in mice with liver-specific Gsalpha deficiency. J Clin Investig. 2005;115:3217–27.CrossRefPubMedPubMedCentral
14.
15.
Khalil BD, Hsueh C, Cao Y, Abi Saab WF, Wang Y, Condeelis JS, et al. GPCR signaling mediates tumor metastasis via PI3Kβ. Cancer Res. 2016;76:2944–53.CrossRefPubMedPubMedCentral
16.
Donini CF, Di ZE, Zuchegna C, Di Domenico M, D’Inzeo S, Nicolussi A, et al. The p85α regulatory subunit of PI3K mediates cAMP-PKA and retinoic acid biological effects on MCF7 cell growth and migration. Int J Oncol. 2012;40:1627–35.PubMed
17.
Bill R, Christofori G. The relevance of EMT in breast cancer metastasis: correlation or causality? FEBS Lett. 2015;589:1577–87.CrossRefPubMed
18.
Ni J, Ramkissoon SH, Xie S, Goel S, Stover DG, Guo H, et al. Combination inhibition of PI3K and mTORC1 yields durable remissions in orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016;22:723–6.CrossRefPubMedPubMedCentral
19.
Liu H, Murphy CJ, Karreth FA, Emdal KB, White FM, Elemento O, et al. Identifying and targeting sporadic oncogenic genetic aberrations in mouse models of triple negative breast cancer. Cancer Discov. 2018;8:354–69.CrossRefPubMed
20.
21.
22.
Peters J, Holmes R, Monk D, Beechey CV, Moore GE, Williamson CM. Imprinting control within the compact Gnas locus. Cytogenet Genome Res. 2006;113:194–201.CrossRefPubMed
23.
Mantovani G, Lania AG, Spada A. GNAS imprinting and pituitary tumors. Mol Cell Endocrinol. 2010;326:15–8.CrossRefPubMed
24.
Ideno N, Ohtsuka T, Matsunaga T, Kimura H, Watanabe Y, Tamura K, et al. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma. Pancreas. 2015;44:311.CrossRefPubMed
25.
Ritterhouse LL, Vivero M, Mino-Kenudson M, Sholl LM, Iafrate AJ, Nardi V, et al. GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas. Mod Pathol. 2017;30:1720–7.CrossRefPubMed
26.
Volckmar AL, Leichsenring J, Flechtenmacher C, Pfarr N, Siebolts U, Kirchner M, et al. Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K–AKT pathway. Genes Chromosom Cancer. 2016;56:11–7.CrossRefPubMed
27.
Garcia-Murillas I, Sharpe R, Pearson A, Campbell J, Natrajan R, Ashworth A, et al. An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer. Oncogene. 2013;33:2478–86.CrossRefPubMedPubMedCentral
28.
Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med. 2014;46:372–83.CrossRefPubMed
29.
Law NC, White MF, Hunzickerdunn ME. G protein-coupled receptors (GPCRs) that signal via protein kinase A (PKA) cross-talk at insulin receptor substrate 1 (IRS1) to activate the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. J Biol Chem. 2016;291:27160–9.CrossRefPubMedPubMedCentral
30.
Suire S, Lécureuil C, Anderson KE, Damoulakis G, Niewczas I, Davidson K, et al. GPCR activation of Ras and PI3Kc in neutrophils depends on PLCb2/b3 and the RasGEF RasGRP4. EMBO J. 2012;31:3118–29.CrossRefPubMedPubMedCentral
31.
Law NC, White MF, Hunzickerdunn ME. G protein-coupled receptors (GPCRs) that signal via protein kinase A (PKA) cross-talk at insulin receptor substrate 1 (IRS1) to activate the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. J Biol Chem. 2016;291(53):27160–9.CrossRefPubMedPubMedCentral
32.
Hunzickerdunn ME, Lopezbiladeau B, Law NC, Daniel WC, Carr DW, Maizels ET. PKA and GAB2 play central roles in the FSH signaling pathway to PI3K and AKT in ovarian granulosa cells. Proc Natl Acad Sci U S A. 2012;109(44):17742–3.
Metadata
Title
Elevated expression of GNAS promotes breast cancer cell proliferation and migration via the PI3K/AKT/Snail1/E-cadherin axis
Authors
X. Jin
L. Zhu
Z. Cui
J. Tang
M. Xie
G. Ren
Publication date
01-09-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 9/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02042-w

Other articles of this Issue 9/2019

Clinical and Translational Oncology 9/2019 Go to the issue

Research Article

Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment

Research Article

Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma

Research Article

The incidence proportion of erectile dysfunction in patients treated with cryotherapy for prostate cancer: a meta-analysis

Research Article

Current management of breakthrough cancer pain according to physicians from pain units in Spain

Brief Research Article

Blockage of autophagic flux is associated with lymphocytosis and higher percentage of tumoral cells in chronic lymphocytic leukemia of B cells

Research Article

Intraoperative blood loss does not independently affect the survival outcome of gastric cancer patients who underwent curative resection
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits